Why the study?
Hypertension and dyslipidemia are highly prevalent, modifiable risk factors in stable ischemic heart disease with guideline-recommended intensive treatment targets.
Intensive management of hypertension and dyslipidemia remains a cornerstone of optimal medical therapy for stable ischemic heart disease.
Intensive BP and LDL-C targets remain appropriate for stable IHD; confirms supporting evidence while leaving precise thresholds open to refinement.
Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs.
No takes yet. Share an insight, caveat, or question.
Abrahams et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: